膀胱灌注RTX治疗间质性膀胱炎的临床研究  

Resiniferatoxin in the treatment of interstitial cystitis

作　　者：杜鹏[1] 朱绪辉[1] 陈松[1] 李涛[1] 严秋哲[1] 杨勇[1] 

机构地区：[1]首都医科大学附属北京朝阳医院西区泌尿外科,北京100043

出　　处：《临床泌尿外科杂志》2008年第10期755-757,共3页Journal of Clinical Urology

摘　　要：目的:探讨膀胱灌注辣椒辣素类似物(resiniferatoxin,RTX)治疗间质性膀胱炎(interstitial cystitis,IC)的有效性和安全性。方法:56例间质性膀胱炎患者行RTX一次性膀胱灌注治疗。观察用药前及用药后1周、1个月、3个月时患者的临床症状情况(每日排尿次数、最大排尿容量、尿痛程度评分)和O′Leary-Sant间质性膀胱炎问卷表评分及生活质量评分(QOL)情况。并记录不良反应发生情况。结果:①患者用药后1周、1个月、3个月时每日排尿次数明显减少(用药前vs用药后1W、1M和3M的每日排尿次数:28.41±10.77 vs 15.30±4.77、15.63±3.70和17.19±4.06),最大排尿容量增加[用药前vs用药后1W、1M和3M的最大排尿容量为:124.26±79.31 vs 187.41±67.46、188.89±62.35和161.85±65.11(ml)],疼痛程度评分明显下降(用药前vs用药后1W、1M和3M的疼痛程度评分为:6.74±1.38 vs 3.89±1.15、4.63±1.31和4.85±1.67),与用药前相比,差异具有统计学意义。②患者用药后1周、1个月、3个月时O′Leary-Sant评分和生活质量评分与用药前相比(O′Leary-Sant评分:用药前vs用药后1W,1M,3M为27.93±4.03 vs 28.04±6.69,27.44±3.89,27.96±4.13;生活质量评分:用药前vs用药后1W、1M、3M为5.52±0.51 vs 5.30±0.47、5.33±0.56、5.44±0.51),比较差异无统计学意义。③所有患者均坚持完成试验,无一例退出。使用RTX后患者生命体征均平稳,其中20例有轻度或中度膀胱或尿道刺激症状,可以耐受,1～3天后均自行消失,无全身不良反应。结论:用RTX膀胱灌注治疗能有效缓解间质性膀胱炎的临床症状和改善其生活质量,且耐受性及安全性好。Objective：To investigate the safety and efficacy of intravesical resiniferatoxin （RTX） therapy for the patients with interstitial cystitis （IC）. Methods：Fifty six patients with IC were involved in this three-month, prospective trial. All the 56 patients received once intravesical RTX therapy. Clinical symptoms （micturition fre quency per day, maximal micturition volume and odynuria degree score）, O＇Leary-Sant IC symptom and problem index, and quality of life score were assessed at baseline and then again after 1 week, 1 month and 3 months of treatment. Side effects was recorded. Results：After 1 week, 1 month and 3 months of treatment, micturition frequency per day（the baseline vs 1 W, 1 M and 3 M after treatment： 28.41±10.77 vs 15.30±4.77, 15.63±3.70 and 17.19±4.06） and odynuria degree score （the baseline vs 1 W, 1 M and 3 M after treatment： 6.74±1.38 vs 3.89±1.15, 4.63±1.31 and 4.85± 1.67）were significantly decreased, and maximal micturition volume [the baseline vs 1W, 1M and aM after treatment： 124.26±79.31 vs 187.41±67.46, 188.89±62.35 and 161.85±65.11（ml）] was significantly increased. There were significantly differences between the baseline and after the treatment. After 1 week, 1 month and 3 months of treatment, O＇Leary-Sant IC symptom and problem index and quality of life score （O＇Leary-Sant IC symptom and problem index： the baseline vs 1W, 1M and 3 M after treatment： 27.93±4.03 vs 28.04±6.69, 27.44±3.89 and 27. 96±4.13; quality of life score： the baseline vs 1W, 1 M and 3 M after treatment： 5.52±0.51 vs 5.30±0.47, 5.33±0.56 and 5.44±0.51）, there were no significantly defference compared with the baseline. There were no serious adverse events after intravesical RTX therapy. No patients withdrawled. 20 of the 56 patients occurred mild or moderate bladder or urethra irritation, but it can be tolerated. The irritation symptom can be relieved after 1 to 3 days without any other intervention measure. Conclusions ： Intravesieal RTX thera

关 键 词：间质性膀胱炎 辣椒辣素类似物(RTX) 治疗 

分 类 号：R694[医药卫生—泌尿科学]